Clinical Determinants of Longitudinal Disability in LGI-1-IgG Autoimmune Encephalitis
Клинические детерминанты долгосрочной инвалидности при аутоиммунном энцефалите с антителами к LGI-1 (LGI-1-IgG)
2023-11-10
SCID: 54.1/errceu9a
Discuss with AI
12-month outcomesClinical Assessment Scale in Autoimmune Encephalitis (CASE)LGI-1-IgG autoimmune encephalitiscognitive impairmentlongitudinal disabilitymemory dysfunctionmodified Rankin Scale (mRS)psychiatric disturbancetemporal lobe T2 hyperintensity
Figures from the paper
Abstract (AI)
Background and Objectives Longitudinal outcome studies in leucine-rich glioma inactivated-1 (LGI-1) immunoglobulin G (IgG) autoimmune encephalitis (AE) are needed to inform clinical management and prognostication. This study aims to evaluate longitudinal predictors of disability and disease severity in LGI-1-IgG AE. Methods This retrospective observational study of patients with LGI-1-IgG AE was conducted between 2013-2022. Disability and disease severity were defined by scores on the modified Rankin Scale (mRS) and the clinical assessment scale in AE (CASE), respectively. Demographic variables, clinical/paraclinical data, brain MRI, and Montreal Cognitive Assessment (MOCA) scores were examined as predictors of mRS and CASE scores in logistic and linear regression models, respectively. Results Thirty patients (60% male, median age = 68.5; interquartile range (IQR) = 63.0–75.0) were included, with a median follow-up time of 19.1 months (IQR = 5.3–47.1) The majority developed seizures (29, [97%]) and/or cognitive impairment (30, [100%]) and received acute (27, [90%]) and maintenance (23 [77%]) immunotherapy. The median initial MOCA was 23/30 (IQR = 21.0–25.0). Baseline mRS (median = 2.0, IQR = 2.0–3.0) and CASE (mean = 4.3, SD = 3.7) correlated with one another (r = 0.58, p < 0.001) and with initial MOCA score (mRS r = –0.60, p = 0.012; CASE r = –0.56, p = 0.021) After 12 months from symptom onset, mRS (OR = 0.88, [95% CI = 0.82–0.94], p < 0.001) and CASE (β = −0.03, [SE = 0.01], p < 0.001) improved significantly. Lower initial MOCA score (OR = 0.68, 95% CI = 0.47–0.98, p = 0.041) and temporal lobe(s) T2 hyperintensity (OR = 16.50, 95% CI = 2.29–119.16, p = 0.006) were associated with higher mRS longitudinally. At last follow-up, most patients had persistent memory dysfunction (25, [83%]) while few had ongoing seizure activity (3, [10%]). Discussion Overall, there was a high degree of correlation between mRS and CASE scores in patients with LGI-1-IgG AE, with both scores improving significantly after 12 months. Memory dysfunction and psychiatric disturbance were the most prevalent longitudinal symptoms. Cognitive impairment and temporal lobe T2 hyperintensity at baseline were both associated with greater disability at long-term follow-up, underscoring these as important determinants of disability outcomes in LGI-1-IgG AE.
Key Findings
1
Baseline cognitive impairment is associated with greater long-term disability.
2
Both mRS and CASE scores show significant improvement after 12 months.
3
Memory dysfunction and psychiatric disturbance are the most prevalent persistent longitudinal symptoms.
4
Modified Rankin Scale (mRS) and Clinical Assessment Scale in Autoimmune Encephalitis (CASE) scores are highly correlated in LGI-1-IgG autoimmune encephalitis patients.
5
Temporal lobe T2 hyperintensity at baseline is associated with greater long-term disability.
Research Object
Patients with LGI-1-IgG autoimmune encephalitis
Research Subject
Clinical determinants of longitudinal disability including baseline cognitive impairment and temporal lobe T2 hyperintensity and their association with long-term disability measured by mRS and CASE scores
Publication Details
Publication Date
2023-11-10
Journal
Publisher
ISSN
Cited by
29
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai2
The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment2005
Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia2010